WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition
(1995; 152 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentPreface
Close this folderProtozoa
Open this folder and view contentsAmoebiasis and giardiasis
View the documentBabesiosis
View the documentFree-living amoebae
Open this folder and view contentsLeishmaniasis
Close this folderMalaria
View the documentChloroquine
View the documentQuinine
View the documentPyrimethamine/sulfadoxine
View the documentPrimaquine
View the documentMefloquine
View the documentHalofantrine
View the documentTetracycline
View the documentDoxycycline
View the documentProguanil
View the documentArtemether
View the documentArtesunate
View the documentArtemisinin
View the documentMiscellaneous intestinal infection
Open this folder and view contentsPneumocystosis
Open this folder and view contentsToxoplasmosis
Open this folder and view contentsTrichomoniasis
Open this folder and view contentsAfrican trypanosomiasis
Open this folder and view contentsAmerican trypanosomiasis
Open this folder and view contentsHelminths
View the documentSelected WHO publications of related interest
View the documentBack cover
 

Artemether

Group: antimalarial agent
Oily solution for injection 80 mg in 1-ml ampoule

General information

Artemether is a lipid-soluble methyl ether of dihydroartemisinin which has very rapid schizontocidal activity against blood forms of P. falciparum and P. vivax. After intramuscular administration, peak plasma concentrations are attained within about 6 hours.

Artemether has been reported to clear fever in severe falciparum malaria within 30-84 hours.

Clinical information

Uses

• Treatment of slide-confirmed severe falciparum malaria in areas where there is evidence that quinine is ineffective. Radical cure should then be effected with a full dose of an effective oral antimalarial such as mefloquine.

Dosage and administration

Adults and children over 6 months: 3.2 mg/kg as a loading dose by intramuscular injection, followed by 1.6 mg/kg daily until the patient is able to tolerate oral medication or for a maximum of 7 days.

Precautions

Artemether should be used for the treatment of severe falciparum malaria only where there is evidence that the antimalarial efficacy of quinine is declining.

For children, since the injected volumes will be small, it is advisable to use a 1-ml syringe to ensure that the correct dose is given.

Use in pregnancy

Little experience has been gained with the use of this drug in pregnancy but it should not be withheld if it is considered life-saving to the mother.

Adverse effects

Neurotoxicity has been observed in animal studies but not in humans.

Cardiotoxicity has been observed following administration of high doses of artemether.

Storage

The oily preparation should be stored in tightly closed containers, protected from light.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: November 5, 2014